(Total Views: 606)
Posted On: 07/28/2019 3:02:44 PM
Post# of 72433
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
I just sent an email to several staff members of "Endpoints News" a pharma news journal:
I'd like to call to your attention the recent press release of IPIX, Innovation Pharmaceuticals, regarding their deal with the Italian pharma co., Alphasigma:
INNOVATION PHARMACEUTICALS ANNOUNCES LICENSE AGREEMENT WITH ALFASIGMA S.P.A. FOR THE DEVELOPMENT AND COMMERCIALIZATION OF BRILACIDIN IN ULCERATIVE PROCTITIS/ULCERATIVE PROCTOSIGMOIDITIS
Brilacidin is been successful in several studies. I hope you will investigate and report about this promising development.
Disclosure: I am a shareholder of IPIX.
Thanks,
gh
I'd like to call to your attention the recent press release of IPIX, Innovation Pharmaceuticals, regarding their deal with the Italian pharma co., Alphasigma:
INNOVATION PHARMACEUTICALS ANNOUNCES LICENSE AGREEMENT WITH ALFASIGMA S.P.A. FOR THE DEVELOPMENT AND COMMERCIALIZATION OF BRILACIDIN IN ULCERATIVE PROCTITIS/ULCERATIVE PROCTOSIGMOIDITIS
Brilacidin is been successful in several studies. I hope you will investigate and report about this promising development.
Disclosure: I am a shareholder of IPIX.
Thanks,
gh
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)